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Abstract 
Background: Moniliformediquinone (MFD), a phenanthradiquinone in Dendrobium moniliforme, was synthesized in 
our laboratory. Beyond its in vitro inhibitory effects on cancer cells, other biological activity of MFD is unknown. The 
purpose of the present study was to investigate the effects of MFD on hepatic fibrogenesis in vitro and in vivo.
Methods: Hepatic stellate HSC‑T6 was cultured. Cell viability assay and western blot analyses were performed. Male 
ICR mice were evaluated on CCl4‑induced hepatotoxicity using both histological examination and immunohisto‑
chemical staining.
Results: First, in vitro study showed that the synthesized MFD effectively attenuated the expression of transforming 
growth factor‑β1 (TGF‑β1), connective tissue growth factor (CTGF), α‑smooth muscle actin (α‑SMA), and type I colla‑
gen (COL‑1), which modulated the hepatic fibrogenesis. Furthermore, MFD reduced the phosphorylation of p65 NFκB 
in HSC‑T6 cells. In vivo, liver fibrosis was induced by CCl4 twice a week for 10 weeks in mice. The administration of the 
MFD was started after 1 week of CCl4 thrice‑weekly; the MFD significantly reduced plasma aspartate transaminase 
(AST) and lactose dehydrogenase (LDH) as well as hepatic hydroxy‑proline, α‑SMA, and COL‑1 expression in CCl4‑
treated mice. Pathological analysis showed that the MFD alleviated CCl4‑induced hepatic inflammation, necrosis and 
fibrosis. These results suggest that MFD possesses therapeutic potential for liver fibrosis.
Conclusions: The synthesized MFD exhibits anti‑fibrotic potential by inactivation of HSCs in vitro and decreases 
mouse hepatic fibrosis in vivo. Further investigation into their clinical therapeutic potential is required.
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Background
Liver cancer is usually an aggressive malignant disease 
with a poor prognosis. Although recent advances have 
been made in the diagnosis and treatment of tumors, the 
development of clinical metastasis remains a significant 
cause of mortality from this disease. Accordingly, hepatic 
fibrosis represents the final pathological outcome for the 
majority of chronic liver insults [1–3]. Untreated fibrosis 
may progress to liver cirrhosis, ultimately leading to 
organ failure, hepatoma and death [4, 5]. Unfortunately, 
effective clinical therapies are still lacking. Liver fibrosis 
is a progressive pathological process as part of the wound 
healing and tissue remodeling mechanism in response to 
chronic liver insults ranging from viral infections to vari-
ous toxins [5, 6]. During liver fibrosis, excessive extracel-
lular matrix (ECM) is produced and accumulated, leading 
to liver dysfunction and irreversible cirrhosis [7, 8]. 
Hepatic stellate cells (HSCs) have been identified as the 
principle cellular source of this ECM, even though sev-
eral other cell types were also recruited to the damaged 
lesions and differentiated to fibroblastic cells. After acute 
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become activated and transdifferentiate into myofibro-
blast-like cells characterized by several key phenotypic 
changes, such as producing excessive extracellular matrix 
(ECM) including type I collagen (COL-1) and α-smooth 
muscle actin (α-SMA). Activated HSCs perpetuate their 
own activation through several autocrine loops, including 
the secretion of transforming growth factor-β1 (TGF-β1) 
and connective tissue growth factor (CTGF) [9]. There-
fore, the modulation function of activated HSCs has been 
proposed as a therapeutic strategy against hepatic fibro-
sis, for instance, decreasing proliferation of HSCs and 
reducing production of ECM and cytokines.
Accordingly, hepatotoxins cause liver damage char-
acterized by varying degrees of hepatocyte degenera-
tion and cell death, such as ethanol, acetaminophen, and 
carbon tetrachloride (CCl4). For instance, CCl4 impairs 
hepatocytes directly by altering the permeability of the 
plasma, lysosomal, and mitochondrial membranes. In 
addition, CCl4-induced liver fibrosis shows many char-
acteristics with human fibrosis of different etiologies 
[10]. Furthermore, CCl4-induced hepatic injury has been 
extensively used in animal models to evaluate the thera-
peutic potential of drugs. On the other hand, plants of 
the Dendrobium genus (Orchidaceae) are used in tradi-
tional herbal medicines in Asia, and studies have shown 
that they contain a wide variety of medicinal properties 
[11–13]. Moniliformediquinone (2,6-dimethoxy-1,4,5,8-
phenanthradiquinone; MFD) (Fig. 1), collected by Chang 
et al. has been isolated from stems of Dendrobium mon-
ilifore (L.) Sw. in Taiwan and has been found to have 
anti-inflammation and anticancer effects [14]. In addi-
tion, our previous study of synthesized MFD showed 
that synthesized MFD could induce in vitro and in vivo 
antitumor activity through a glutathione-involved DNA 
damage response and mitochondrial stress in human 
hormone refractory prostate cancer [15]. Other biologi-
cal activities of MFD are unknown. In the present study, 
the anti-hepatic fibrosis potential of synthesized MFD 
was evaluated using HSC-T6, an activated HSC cell line, 
and a mouse model of CCl4-induced hepatic injury. Fur-
ther study aimed to investigate the effect of synthesized 
MFD on the expression of activated HSC-T6 markers 
and fibrosis-related proteins and its relationship with the 
expression of TGF-β1, α-SMA, and COL-1. Finally, path-
ological analysis showed that the synthesized MFD could 
possess therapeutic potential for liver fibrosis.
Methods
Chemicals
Dulbecco’s modified Eagle’s medium (DMEM), phos-
phate-buffered saline (PBS), fetal bovine serum, l-glu-
tamine, penicillin/streptomycin (PS), and trypsin-EDTA 
were purchased from GIBCO Ltd. (Grand Island, NY, 
USA). Anti-CTGF, α-SMA, and α-tubulin antibodies 
were provided from Santa Cruz Biotechnology (Santa 
Cruz, CA). Anti-TGF-β1 was obtained from Cell signal-
ing Technology (Beverly, MA). Other chemical reagents 
were purchased from Sigma-Aldrich.
The 2,6-dimethoxy-1,4,5,8-phenanthrenetetrone, mon-
iliformediquinone (MFD), was prepared as previous pro-
cedure [16]. Melting point and 1H and 13C NMR spectra of 
the synthetic MFD are in agreement with those reported 
for the natural product [14]. Thus, the drug of synthetic 
MFD is >95 % purity (13C NMR peak purity test) for fol-
lowing bioassay. The TdT-mediated dUTP Nick End Labe-
ling (TUNEL) kits were purchased from Roche (Germany).
Cell culture and MTT assay
The immortalized hepatic stellate cell line (HSC-T6) 
and murine liver cell (BNL CL.2) were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) plus 
10  % (v/v) fetal bovine serum, penicillin-streptomy-
cin (100  IU/mL–100  μg/mL), and incubated at 37  °C 
in a 5  % CO2 humidified atmosphere. Cell viabil-
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Fig. 1 a Chemical structure of moniliformediquinone (MFD). b Effect 
of MFD on cell viability of HSC‑T6 cells. HSC‑T6 cells were treated with 
MFD (0–2.5 μM) for 24 and 48 h. MTT assays were performed to assess 
cell viability. The data represent mean ± SD of three independent 
experiments. *P < 0.01 versus the control
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(2–5  ×  104  cells/well) were seeded in 24-well culture 
plates and exposed to different concentrations of mon-
iliformediquinone for 24  h. Next, the medium was 
changed and the cells were incubated with MTT (5 mg/
mL) for 4  h. Finally, the absorbance of the formazan 
product was measured at a wavelength of 570 nm on an 
ELISA reader [17].
Preparation of total cell extracts and immunoblots analysis
Cells (1  ×  106  cells/well) were seeded in 10-cm dishes 
in the presence of the MFD. The cells were collected by 
trypsin-EDTA and lysed in RIPA buffer (50  mM Tris-
HCl, 1  mM EDTA, 150  mM NaCl, 1  % NP-40) contain-
ing protease inhibitors. After mixing for 30 min at 4  °C, 
the mixtures were centrifuged (10,000×g) for 10  min at 
4  °C and the supernatants were collected as whole-cell 
extracts. The protein content was determined using the 
Bio-Rad protein assay reagent and bovine serum albumin 
as a standard. An equal amount of protein from the total 
cell extracts was boiled for 8 min. The extracts were sepa-
rated by SDS-polyacrylamide gels and transferred to a NC 
membrane (Whatman). The blots were blocked in 5  % 
non-fat dry milk/PBS for 1  h at room temperature. The 
blots then were incubated overnight with primary anti-
bodies, followed by horseradish peroxidase-conjugated 
goat anti-mouse (or rabbit) IgG for 1 h. The immunoreac-
tive bands were revealed by enhanced chemiluminescence 
with a commercially available ECL kit [18].
Animals
Male ICR mice (body weight 18–22  g) were purchased 
from GlycoNex Inc. (Taiwan) and maintained in cage 
housing in a specifically designed pathogen-free isola-
tion facility with a 12/12 h light/dark cycle. Animal care 
and the general protocols for animal use were approved 
by the Institutional Animal Care and Use Committee of 
Chung Shan Medical University Animal Ethics Research 
Board. All mice of CCl4-treated alone and combined 
MFD administration group were given 0.1  mL/mice of 
CCl4 (20 % CCl4 in olive oil) via intragastric twice a week 
for 10 weeks. The mice were intraperitoneal injected with 
0.1 and 0.5 mg/kg of MFD thrice a week. Those in control 
and MFD-treated alone groups were given equal volume 
of olive oil. The mice were divided randomly into five 
groups of eight mice each. Then, the mice were sacrificed 
24 h after the last injection. The livers were divided into 
two portions (1) preserved in 10 % formalin for histologi-
cal examination, (2) frozen for immunoblotting analysis 
at −70 °C.
Biochemical assays
Blood was obtained by intra-cardiac puncture from 
mice. Serum was separated and levels of alanine 
aminotransferase (AST) and lactate dehydrogenase 
(LDH) were measured using standard enzymatic assay 
kits. Each assay is a colorimetric assay with detection of 
a highly colored end product measured at 490–520 nm. 
The absorbance of each end product is proportional to 
the enzyme’s activity [19].
Liver samples were lysed in radioimmunoprecipitation 
assay (RIPA) buffer containing 50  mM Tris-HC pH 7.4, 
150 mM NaCl, 1 % NP-40, 0.5 % sodium deoxycholate, 0.1 % 
SDS, 2  mM phenylmethylsulfonyl fluoride, 1  mM sodium 
orthovanadate, and 2 μg/mL of each leupeptin and pepsta-
tin. Volume equivalent to 50 μg of proteins was analyzed by 
western immunoblotting assay as previous description.
Histopathological analysis
Liver tissues from each mouse were rapidly removed, 
fixed in 10  % neutral-buffered formalin, and processed 
routinely. Paraffin-embedded sections were cut into 4 μm 
thick sections. The sections were stained with hematoxy-
lin and eosin (H&E) and with Masson’s trichome for col-
lagen fibers [20].
Immunohistochemistry
Immunohistochemistry (IHC) staining was performed 
using a biotinylated secondary antibody (Vectastain Uni-
versal Elite ABC Kit, Burlingame, CA, USA). Monoclonal 
rabbit antibodies against peroxiredoxin 2 and alpha-1-an-
tiproteinase were diluted at a ratio of 1:100. The omission 
of primary antibodies was used as the negative control. For 
three slides, cytoplasm that was stained brown was scored 
as positive. The expression of hydroxy-proline, α-SMA and 
COL-1 were quantitatively evaluated using an Olympus 
CX31 microscope (Tokyo, Japan) with the Image-pro Plus 
medical image analysis system. Digital images were cap-
tured using a digital camera (Canon A640, Tokyo, Japan). 
The positive area and optical density (OD) of hydroxy-
proline, α-SMA and COL-1 positive cells were determined 
by measuring three randomly selected microscopic fields 
(400× magnification) for each slide. The IHC index was 
defined as the average integral optical density (AIOD) 
(AIOD = positive area × OD/total area) [21].
Statistical analysis
All experiments were carried out in triplicate, and data 
were expressed as mean ± SD. One-way analysis of vari-
ance (ANOVA) and the Duncan test were carried out to 
determine significant differences of multiple comparisons. 
Significance was defined as a P value of less than 0.05 [19].
Results
Cytotoxicity of MFD in HSC‑T6 and BNL CL.2 cells
Figure  1 shows the effects of various concentrations of 
MFD on activated HSCs (HSC-T6) and normal murine 
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liver cells (BNL CL.2). After treatment for 48  h. MFD 
showed a cytotoxicity effect on HSC-T6 cells above 
0.5  μM concentrations whereas the applied concentra-
tion showed noncytotoxicity on BNL CL.2 cells.
Effect of MFD on the expression of TGF‑β, CTGF, α‑SMA, 
COL‑1 in HSC‑T6 cells
Transforming growth factor-β1 (TGF-β1) is a major 
fibrotic growth factor in liver fibrosis [9]. CTGF is selec-
tively induced by TGF-β in a fibroblastic cell type and 
plays a key role in the overproduction of ECM in acti-
vated HSCs. Therefore, we determined the levels of TGF-
β1 and CTGF after treatment with MFD in HSC-T6 cells 
using western blot analysis. The results showed that MFD 
significantly decreased the protein level of TGF-β1 and 
CTGF (Fig. 2a). In addition, the most striking biological 
consequences of activated HSCs are the marked accu-
mulation of α-SMA and the dramatic increase in colla-
gen depositions. MFD reduced the levels of α-SMA and 
COL-1 after treatment with MFD in HSC-T6 cells as 
compared with the control (Fig. 2a). Furthermore, MFD 
inhibited the phosphorylation of p65 NFkB (Fig.  2a), 
which has been suggested to be associated with the regu-
lation of TGF-β1 expression [22]. To confirm the impor-
tant role of TGF-β1 affected by MFD, TGF-β1 was added 
to promote the expression of CTGF, α-SMA, and COL-
1. As shown in Fig.  2b, MFD reduced the expression of 
CTGF, α-SMA, and COL-1, which were mediated by 
TGF-β1.
Inhibitory effect of MFD on CCl4‑induced hepatotoxicity 
in mice
In order to evaluate hepatic tissue damage, serum enzyme 
levels of LDH and AST with/without CCl4-treated mice 
were determined by using standard enzymatic kits. As 
shown in Fig.  3, serum LDH and AST activity in mice 
treated with MFD alone did not significantly differ from 
that of the control group. AST and LDH activity of all 
CCl4-treated mice increased significantly as compared 
with that of the control group after the end of the experi-
ment (P  <  0.001). However, administration of the MFD 
significantly suppressed the CCl4-induced increase of 
LDH and AST activity, respectively (P < 0.01, P < 0.001).
MFD inhibits CCl4‑induced TGF‑β1, α‑SMA and COL‑1 
expression in mouse liver
The TUNEL assay results are shown in Fig.  4. Global 
immunoreactivity to apoptosis was localized primarily 
within liver tissue in CCl4 mouse. Quantitative examina-
tion of hepatocyte pathology showed that the number 
of normal hepatocytes present in the CCl4 treatment 
group was lower than the number of normal hepatocytes 
present in the control groups (control group  =  5  ±  1; 
CCl4 treatment group = 65 ± 3; 0.1 mg/kg MFD treated 
CCl4 = 30 ± 3; 0.5 mg/kg MFD treated CCl4 = 15 ± 3, 
P < 0.05). We employed immunohistochemistry to exam-
ine liver hydroxy-proline protein expression in the hepat-
ocyte of the untreated control and MFD alone group, the 
CCl4 group and the two CCl4 + MFD groups, which acts 
as an index of oxidative damage in hepatic fibrosis, was 
measured in order to investigate the therapeutic effect 
of MFD. A significant reduction in hydroxy-proline was 
found in the CCl4 + MFD groups compared to the CCl4 
group. Significantly decreased expression of α-SMA, and 
COL-1 proteins were found in the MFD groups com-
pared to the CCl4 group, P < 0.05 (Fig. 4).
Histopathological examination
As shown in Fig.  5, in vehicle control and MFD-only-
treated mice, liver sections showed normal hepatic 
cells, i.e., with a well-preserved cytoplasm, a prominent 
nucleus, and a central vein. The livers of CCl4-intoxi-
cated mice revealed moderate to severe hepatocellular 
vacuolization, hepatic necrosis, and inflammatory cell 
filtration. Against the pathological changes, the lesions 
of the 0.5  mg/kg MFD-treated mice were of a much 
milder degree compared with the lesions observed in 
the group treated with CCl4 alone. In addition, the col-
lagen of fibrotic tissues showed a blue color when stained 
by Masson’s trichrome. There was no fibrosis in either 
the control group or the group treated with MFD alone. 
In contrast, a large number of blue collagen fibers were 
observed in the CCl4-treated mouse (Fig.  5). In the 
0.5 mg/kg MFD-treated group, the extent and area of the 
collagen fibers was apparently reduced (Table 1).
Discussion
Hepatic stellate cells (HSC) are considered to play a key 
role in the pathogenesis of liver fibrosis. During liver 
fibrogenesis, HSCs are activated and acquire a myofibro-
blast-like phenotype that is accompanied by increased 
proliferation and extracellular matrix synthesis [23, 24]. 
Therefore, suppression of HSC activation has been pro-
posed as a therapeutic target against hepatic fibrosis. In 
the present study, synthesized MFD was measured for 
its anti-fibrotic activities by assessing the effect on the 
suppression expression of fibrotic-associated protein. 
α-SMA is a definite marker of transdifferentiation of 
stellate cells. The experimental data showed that MFD 
reduced α-SMA expression in HSC-T6 cells and in the 
liver of the CCl4-treated mouse (Figs. 2, 4). Furthermore, 
collagens such as COL-1 are the main components of the 
ECM, and the main collagen-producing cells in the liver 
are HSCs. The present study found that MFD decreased 
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Fig. 2 Effect of MFD on the expression of activated HSC‑T6 markers and fibrosis‑related proteins. HSC‑T6 cells were treated with various concentra‑
tions of MFD for 48 h; then total cell lysates were tested for (a) TGF‑β1, CTGF, α‑SMA, COL‑1 and p‑p65 NFκB by western blot analysis. b HSC‑T6 cells 
were treated with TGF‑β1 (2 ng/mL) alone or in combination with different concentrations of MFD for 48 h; then total cell lysates were analyzed by 
western blot analysis against anti‑CTGF, anti‑α‑SMA, anti‑COL‑1, and anti‑β‑actin as an internal control. Quantification of band intensity relative to 
α‑tubulin is shown below the western blot. The quantitative data were presented as the mean of three repeats from one independent experiment. 
The data were presented as mean ± SD of three independent experiments. #P < 0.05 versus control. *P < 0.05, versus TGF‑β1‑treated alone
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COL-1 expression in HSC-T6 cells and in the liver of the 
CCl4-treated mouse (Figs.  4, 5). These results showed 
that MFD can inhibit HSCs activation. In addition, it first 
demonstrated, in vitro and in vivo, an anti-fibrotic effect 
of MFD, which has been isolated from the Dendrobium 
monilifore stem. Moreover, phenanthrenes from the 
Dendrobium nobile stem have previously been shown to 
exhibit anti-fibrotic potential [13]. Consistent with these 
findings, the Dendrobium species is thought to be use-
ful for developing therapeutic agents for the treatment of 
hepatic fibrosis.
Many studies have evaluated candidate anti-fibrosis 
factors or reagents by assessing their impact on TGF-
β-induced collagen and α-SMA expression in fibro-
blasts. For instance, TGF-β1 is a pleiotropic cytokine 
involved in the activation of HSCs, the main producers 
of ECM components in the liver [25]. In general, TGF-
β1 induces the expression of type I collagen and inhib-
its apoptosis of HSCs. It is also suggested that TGF-β1 
can up-regulate the platelet-derived growth factor beta 
(PDGF-β) receptor, resulting in a proliferation response 
in activated HSCs [26]. As shown in Fig.  3, MFD 
inhibited DNA synthesis in correlation with reduc-
ing the expression of TGF-β1. There are many regula-
tors involved in the inflammation-fibrosis process, and 
the NFκB signaling pathway appears to play a critical 
role in liver homeostasis, pathophysiology, and regu-
lation of inflammation-fibrosis [27]. NFκB is found in 
activated HSC [28], where it is involved in upregulat-
ing proinflammatory gene encoding adhesion mole-
cules, chemokines, and cytokines such as TGF-β1. Our 
study found that MFD inhibited the phosphorylation 
of p65 NFκB and the expression of TGF-β1 (Fig. 2a, b). 
NFκB was also involved in the protection of HSC from 
apoptosis. Suppression of NFκB may increase apopto-
sis of HSC. As shown in Fig.  2b, MFD can reduce the 
TGF-β1-stimulating expression of α-SMA, COL-1, and 
CTGF, which are downstream of TGF-β1. These data 
imply that MFD possesses an anti-fibrogenesis effect 
by inhibiting HSCs activation associated with block-
ing the NFκB signaling pathway and reducing TGF-β1 
expression. The molecular mechanism of the signal-
ing pathway regulated by MFD in HSC needs further 
clarification.
Hepatic fibrosis, a leading cause of morbidity and 
mortality worldwide, is usually associated with chronic 
liver disease. Hepatic fibrosis can develop into cir-
rhosis within 1–10  years [29]. Thereafter, blocking the 
progression of fibrosis may be an efficacious strategy 
to survival. As a consequence, CCl4-induced hepatic 
MFD (mg/kg)





















Fig. 3 Effects of MFD on serum AST and LDH in CCl4‑treated mice. The data for serum LDH and AST are presented as mean ± SD from six mice per 
group. #P < 0.05, as compared to the control group; *P < 0.05, as compared to the CCl4‑treated group






















































Fig. 4 Effect of MFD on the liver fibrosis‑related protein expression in CCl4‑treated mouse liver. Histological examination of liver were revealed 
as indicated by immunohistochemical staining of TUNEL. Hydroxy‑proline, α‑SMA and COL‑1 were evaluated by immunohistochemical staining. 
Representative liver sections stained as oil infusion control group (I); Mice with MFD treatment (II); Mice with CCl4 injection (III); MFD treatment 
(0.1 and 0.5 mg/kg) (IV, V); Magnification, ×200. The cells were counted from 10 fields (×200 magnification) of each liver sample. The results from 
statistical analysis are the means of cells and were calculated per microscope field from eight animals per group. Data are expressed as mean ± SD 
of independent experiments. *P < 0.05, as compared to the CCl4‑treated group
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injury is an experimental model used for drug screening 
[30]. In addition, AST and LDH are enzymatic indica-
tors of tissue damage by toxicants or disease condition, 
and abnormal levels of AST and LDH are important 
to pathology and toxicology. According to our in  vivo 
study, administration of MFD significantly reduced 
the level of AST and LDH as compared with the group 
treated with CCl4 alone (Fig. 3). In addition, MFD inhib-
ited CCl4-induced hepatic fibrotic factor expression 
such as hydroxy-proline, α-SMA, and COL-1 (Fig.  4). 
Histopathological examination showed that 0.5  mg/
kg MFD apparently decreased CCl4-induced hepatic 
inflammation, necrosis, and fibrosis (Fig.  5). These 
results demonstrated that the synthesized MFD can 
block CCl4-induced hepatic damage and fibrotic pro-
gression. Based on our results, it makes possible that 
cultured HSC underwent a rapid and persistent induc-
tion NF-kB, while the inhibition of NF-kB as well as 
CTGF, α-SMA and COLI by MFD were required in a 
dose-dependent. In this study, we investigated MFD has 
an inhibitory effect on the CCl4 model of hepatocyte 
injury that is cytotoxic to serious fibrotic liver in  vivo. 
Further investigation is required to better understand 
whether when CCl4 infusion in rats were established 
as model of liver dysfunction and fibrogenesis, treat-
ment with MFD induced a significant dose-dependent 
decrease in liver fibrosis for a period of time points. 
These results provide insights into the therapeutic activ-
ity of MFD, which thus may be promising candidates 
for the treatment of liver injury diseases such as hepatic 
fibrosis.
Conclusions
In summary, this study concludes that the synthesized 
MFD exhibits anti-fibrotic potential by inactivation 
of HSCs in  vitro and decreases mouse hepatic fibrosis 
in  vivo. Further investigation into their clinical applica-
tion is required.
H&E Massona b
Fig. 5 Effect of MFD on histological changes in the liver of CCl4‑
treated mice. Lliver sections stained as oil infusion control group 
(I); mice with MFD treatment (II); mice with CCl4 injection (III); MFD 
treatment (0.1 and 0.5 mg/kg) (IV, V); the section of mouse liver was 
stained with a hematoxylin‑eosin or b Masson’s trichrome (magnifica‑
tion ×200)
Table 1 MFD exhibits anti-fibrotic potential by decreasing mouse hepatic fibrosis in vivo
Inflammation Degeneration Hepatocyte necrosis Fibrosis
Control − − − −
MFD alone − − −
CCl4 alone +++ ++ +++ +++
CCl4 + MFD (0.1 mg/kg) +++ ++ +++ ++
CCl4 + MFD (0.5 mg/kg) ++ + + +
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